Dr Salmon completed her PhD in 2009, investigating the role of transcription factors in (i) the development and maintenance of hematopoietic stem cells and (ii) differentiation of the myeloid lineage. This work resulted in first author publications in Blood and Cell Stem Cell.
During her post-doctoral research, Dr Salmon directed her work towards exploring novel therapeutics for the treatment of acute myeloid leukaemia (AML). These studies focussed primarily on investigating the efficacy of HDAC-inhibitors against AML, when used either alone or in combination with other agents. This work has been published in Blood and Clinical Epigenetics, with additional manuscripts in preparation.
Dr Salmon has been involved in large collaborative clinical trial studies, including the processing and analysis of patient samples. These studies have led to several high impact publications in Leukaemia, Blood and J Clin Oncol, and have contributed to the clinical use of venetoclax in combination with low-dose chemotherapy for elderly AML. She has presented this work both nationally and internationally and has been the recipient of peer-reviewed grant funding, as CIA, from Cancer Australia and the Alfred Research Foundation.